Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (20)
Loretta J. Nastoupil. (2022) Navigating the Treatment Landscape of Advanced Follicular Lymphoma: Should You Consider a CAR, and Which Model?. The Hematologist 19:2.
Crossref
Crossref
Max L. Goldman, Jimmy J. Mao, Christopher S. Strouse, Wanqi Chen, Manali Rupji, Zhengjia Chen, Matthew J. Maurer, Oscar Calzada, Michael Churnetski, Christopher R. Flowers, James R. Cerhan, Brian K. Link, Carrie A. Thompson & Jonathon B. Cohen. (2021) Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer 127:18, pages 3390-3402.
Crossref
Crossref
Ciara L. Freeman & Laurie H. Sehn. (2020) Initial Treatment of High Tumor Burden Follicular Lymphoma. Hematology/Oncology Clinics of North America 34:4, pages 673-687.
Crossref
Crossref
Loretta J. Nastoupil. 2020. Follicular Lymphoma. Follicular Lymphoma
207
218
.
Frederick W. Thielen, Nasuh C. Büyükkaramikli, Rob Riemsma, Debra Fayter, Nigel Armstrong, Ching-Yun Wei, Vanesa Huertas Carrera, Kate Misso, Gill Worthy, Jos Kleijnen & Isaac Corro Ramos. (2018) Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma. PharmacoEconomics 37:8, pages 975-984.
Crossref
Crossref
Laura Magnano, Sara Alonso‐Alvarez, Miguel Alcoceba, Alfredo Rivas‐Delgado, Anna Muntañola, Ferran Nadeu, Xavier Setoain, Sonia Rodríguez, Marcio Andrade‐Campos, Natalia Espinosa‐Lara, Guillermo Rodríguez, Juan Manuel Sancho, Miriam Moreno, Santiago Mercadal, Itziar Carro, Antonio Salar, Francesc Garcia‐Pallarols, Reyes Arranz, Jimena Cannata, María J. Terol, Ana I. Teruel, Ana Jiménez‐Ubieto, Antonia Rodriguez, Sonia González de Villambrosía, José L. Bello, Lourdes López, Silvana Novelli, Erik Cabo, María E. Infante, Emilia Pardal, Silvia Monsalvo, Marcos González, Alejandro Martín, M. Dolores Caballero & Armando López‐Guillermo. (2019) Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. British Journal of Haematology 185:3, pages 480-491.
Crossref
Crossref
Gwynivere A. Davies, Sunita Ghosh, Danielle H. Oh, Mita Manna, Anthea C. Peters, Colin A. Stewart & Douglas A. Stewart. (2018) The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:12, pages 829-835.
Crossref
Crossref
Mayur S. Narkhede & Bruce D. Cheson. (2018) Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:7, pages 447-451.
Crossref
Crossref
Melody R. Becnel & Loretta J. Nastoupil. (2018) Follicular Lymphoma: Past, Present, and Future. Current Treatment Options in Oncology 19:7.
Crossref
Crossref
Loretta J. Nastoupil, Jean L. Koff, Leon Bernal-Mizrachi & Christopher R. Flowers. 2018. The American Cancer Society's Oncology in Practice. The American Cancer Society's Oncology in Practice
444
462
.
Marc Sorigue, Santiago Mercadal, Sara Alonso, Ruben Fernández-Álvarez, Olga García, Miriam Moreno, Helena Pomares, Miguel Alcoceba, Esther González-García, Cristina Motlló, Eva González-Barca, Alejandro Martin, Anna Sureda, Dolores Caballero, Josep-María Ribera & Juan-Manuel Sancho. (2017) Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. Hematological Oncology 35:4, pages 520-527.
Crossref
Crossref
C. Casulo, L. Nastoupil, N.H. Fowler, J.W. Friedberg & C.R. Flowers. (2017) Unmet needs in the first-line treatment of follicular lymphoma. Annals of Oncology 28:9, pages 2094-2106.
Crossref
Crossref
Wojciech Jurczak, Ilídia Moreira, Govind Babu Kanakasetty, Eduardo Munhoz, Maria Asunción Echeveste, Pratyush Giri, Nelson Castro, Juliana Pereira, Luiza Akria, Sergey Alexeev, Eugeniy Osmanov, Peijuan Zhu, Siyka Alexandrova, Angela Zubel, Olof Harlin & Jutta Amersdorffer. (2017) Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. The Lancet Haematology 4:8, pages e350-e361.
Crossref
Crossref
Loretta J. Nastoupil, Peter McLaughlin, Lei Feng, Sattva S. Neelapu, Felipe Samaniego, Fredrick B. Hagemeister, Ana Ayala, Jorge E. Romaguera, Andre H. Goy, Eleanor Neal, Michael Wang, Luis Fayad, Michelle A. Fanale, Yasuhiro Oki, Jason R. Westin, Maria A. Rodriguez, Fernando Cabanillas & Nathan H. Fowler. (2017) High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. British Journal of Haematology 177:2, pages 263-270.
Crossref
Crossref
Laura Magnano, Silvia Montoto, Eva González-Barca, Javier Briones, Juan Manuel Sancho, Ana Muntañola, Antonio Salar, Joan Besalduch, Lourdes Escoda, Carol Moreno, Eva Domingo-Domenech, Cristina Estany, Albert Oriol, Albert Altés, Carmen Pedro, Santiago Gardella, Antoni Asensio, Pilar Vivancos, Alberto Fernández de Sevilla, Josep María Ribera, Dolors Colomer, Elias Campo & Armando López-Guillermo. (2017) Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. Annals of Hematology 96:4, pages 639-646.
Crossref
Crossref
Qian ShiChristopher R. FlowersWolfgang HiddemannRobert MarcusMichael HeroldAnton HagenbeekEva KimbyHoward HochsterUmberto VitoloBruce A. PetersonEmmanuel GyanMichele GhielminiTina NielsenSabine De BedoutTommy FuNancy ValenteNathan H. FowlerEva HosterMarco LadettoFranck MorschhauserEmanuele ZuccaGilles SallesDaniel J. Sargent. (2017) Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. Journal of Clinical Oncology 35:5, pages 552-560.
Crossref
Crossref
Marcio Miguel Andrade-Campos, Paola Liévano, Natalia Espinosa-Lara, Gloria Soro-Alcubierre, José María Grasa-Ulrich, Luis López-Gómez, Teresa Baringo & Pilar Giraldo. (2016) Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan. European Journal of Haematology 97:6, pages 576-582.
Crossref
Crossref
Loretta J. Nastoupil, Rajni Sinha, Michelle Byrtek, Ryan Ziemiecki, Xiaolei Zhou, Michael Taylor, Jonathan W. Friedberg, Brian K. Link, James R. Cerhan, Keith Dawson & Christopher R. Flowers. (2016) Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. British Journal of Haematology 172:5, pages 724-734.
Crossref
Crossref
Jonathon B. Cohen, Jeffrey M. Switchenko, Jean L. Koff, Rajni Sinha, Jonathan L. Kaufman, H. Jean Khoury, Nassoma Bumpers, Amanda Colbert, Amanda Hutchison-Rzepka, Loretta J. Nastoupil, Leonard T. Heffner, Amelia A. Langston, Mary Jo Lechowicz, Sagar Lonial & Christopher R. Flowers. (2015) A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. British Journal of Haematology 171:4, pages 539-546.
Crossref
Crossref
Jonathon B Cohen, David M Kurtz, Ashley D Staton & Christopher R Flowers. (2015) Next-generation surveillance strategies for patients with lymphoma. Future Oncology 11:13, pages 1977-1991.
Crossref
Crossref